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Abstract 
There are a number of predisposing factors in the development of human 
thyroid carcinoma, but the underlying pathogenesis of thyroid carcinoma 
remains unknown. One of the specific features of thyroid cancer is its 
predilection for women of reproductive age relative to men. The incidence of 
thyroid tumors and carcinomas is three times more frequent in females than 
males. An elevated risk was also documented in women who used estrogens 
for gynecological problems, but not for low dose estrogen replacement therapy 
in postmenopausal women. The presence of estrogen receptors in thyroid 
tissues was demonstrated by immunohistochemical method. In some studies, 
higher levels of ERs were found in neoplastic thyroid tissues but not in normal 
thyroid tissues. These epideminological and experimental studies indicate that 
estrogen may play a pathological role in thyroid carcinoma. 
In this study, we investigated the effect of estrogen (estradiol, E2) on 
apoptosis in the well-differentiated human thyroid carcinoma (KAT5) cell. 
The KAT5 cells were treated with lO''', 10'^ lO'^M/L E2 for 24 and 48 hours. 
We examined the cell proliferation of the E2 treated KAT5 cells and compared 
it with that of the testosterone treated KAT5 cells by MTT assay. The growth 
I 
effect of E2 was also attenuated by tamoxifen. We have studied the expression 
of the estrogen receptor (ER), anti-apoptotic Bcl-xL and pro-apoptotic Bax 
protein and mRNA levels in KAT5 cells by western blot and RT-PCR analysis. 
The protein expression of the anti-apoptotic potential (Bcl-xL/Bax ratio) 
I 
increased in the dose-dependent manner. The results indicate that the 
mechanism of action of estrogen on KAT5 cell growth may be associated with 











(KAT5)的細胞生長及細胞调亡的影響。KAT5細胞經 ICT"，10_ 9 ’ 
和 l ( r 7 M / L 雌二醇治療 2 4 和 4 8 小時後，我們利用 M T T 分析測 
試雌二醇對細胞生長的影響，同時也比較了其與雄激素對細胞生 
長的影響的不同。雌二醇對細胞生長的影響可被 t a m o x i f e n所減 
輕。另外，我們用Western b l o t和R T - P C R分析測試雌激素受體， 
抗调亡B c l - x L和促调亡B a x蛋白及m R N A在 .細胞的表達狀況。 
雌激素雖對B a x的表達無顯著的影響，但可明顯增加B c l - x L的水 
平，因而，雌激素可以劑量依靠方式增加抗调亡潛勢（Bcl-xL/Bax 
比率）。總括結果’雌激素對甲狀腺癌K A T 5細胞成長具有抑制 
作用 ,此抑制作用可能與其提升B C 1 - X L的表達有聯。 
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CHAPTER ONE: INTRODUCTION AND LITERATURE 
1.1 THYROID CANCER AND ITS EPIDEMIOLOGY 
Thyroid cancer is a relatively rare cancer accounting for approximately 
1 % of all cancers in worldwide (Correa et al, 1995). However, it is 
the highest incidence of cancer of endocrine gland. The incidence rate 
shows the striking worldwide similarities in the female excess of 
thyroid cancer in a specific age group. 
1.1.1 Histology 
Cancer of the thyroid is comprised of four primary histological types. 
Anaplastic cancers, which also arise from follicular cell, are 
undifferentiated. They occur primarily in the elderly, and are 
associated with a much poorer prognosis. Medullary cancers arise from 
the calcitonin-secreting parafollicular cells. Papillary and follicular 
cancers are the well-differentiated thyroid cancers arise from follicular 
cells, and they occur primarily in young to middle-aged women 
(Correa et al., 1995). They are the most common histological types of 
thyroid cancer. For instance, among all thyroid cancer cases diagnosed 
between 1998 to 1999 and identified in the Hong Kong cancer registry 
(Table 1)，the distribution by histology was 77.4 % papillary, 12.6 % 
follicular, 1.8 % medullary, and 2.4% anaplastic, with the remainder 
1 
categorized as "others". The histological distribution is similar in Japan 
and United States (Koike et al., 1991 and Gilliland et al., 1997). 
Histology Male % Female % Total o/o 
Papillary carcinoma 140 74.9 467 78.2 607 77.4 
Follicular carcinoma 19 10.2 80 13.4 99 12.6 
Medullary Carcinoma 5 2.7 9 1.5 14 1.8 
Anaplastic Carcinoma 12 6.4 7 1.2 19 2.4 
i 
Other specified carcinoma 4 2.1 4 0.7 8 1.0 
. • • ‘ — ‘ — — ^ ― — — — — — — — ^ ^ ― ^ ― ― ― ‘ ‘ • I ] 
Unspecified carcinoma 1 0.5 7 1.2 8 1.0 
Other specified morphology 1 0.5 - 0.0 1 0.1 
•Unspecified morphology 5 2.7 23 3.9 28 3.6 
Total ^ 1 8 7 100 597 100 784 100.0 
* "Unspecified morphology" includes all cases that have no microscopic 
verification of diagnosis or the results are not interpretable. 
Table 1. Thyroid Cancer Histological subtype in Hong Kong (1998-1999). 
(Hong Kong Cancer Registry). 
2 
1.1.2 Gender comparison 
Throughout the world, age-adjusted incidence rates for thyroid cancer 
show 2-to 3-fold excess among females relative to males (Figure 1). 
The female: male ratio varies by age and histology. Age-specific 
incidence data from Los Angeles County (Figure 2) show that the 
female: male rate ratio is highest from ages 15 to 40, ranging from 3.1 
to 6.0. The female excess remains approximately double from age 40-
55 and declines thereafter. Among almost 12,000 cases of thyroid 
cancer diagnosed among whites in 1973-1987 and identified in the 
United States Surveillance, Epidemiology, and End Results cancer 
registry (SEER), the female: male ratio was 2.6 for papillary cancer, 
2.2 for follicular cancer, 2.0 for medullary cancer, and 1.0 for 
anaplastic cancer (Correa et al, 1995). This predilection for women of 
reproductive age phenomenon makes a hint on the pathogenesis of 
thyroid cancer. In their reproductive age, normal females have a range 
of 180-1500 pmol/1 endogenous estrogen in the blood circulation. After 
the reproductive age, the endogenous estrogen level is lowered to less 
than 200 pmol/1 in the circulation system of the female. In contrast, the 
endogenous estrogen level is less than 300 pmol/1 in men. Therefore, 
estrogen has been suspected as one of the factors that contribute to the 
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Figure 1. Age-adjusted incidence rates (per 100,000) of thyroid cancer, 1983-
1987 (Parkin et al., 1992). 
*SEER=Surveillance, Epidemiology, and End Results cancer registry 
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Figure 2. Age-specific incidence rates (per 100,000) of thyroid cancer 
by gender in Los Angeles County, 1972-1995 (Fagin，Thyroid Cancer. 
1998). 
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1.1.3 Female Hormone - A Risk Factor 
In animal studies, thyroid tumors induced by N-methyl-N-nitrosourea 
and a low iodine diet were more frequent in female than male rats 
(Mori et al, 1990). Thyroid weight and serum thyroid-stimulating 
hormone (TSH) was also higher in female than in male rats. Relative to 
gonadectomized rats not given estrogen, the administration of estrogen 
increased thyroid weight, TSH, and the incidence of thyroid tumors in 
castrated and ovarectomized rats. These studies suggested that 
endogenous estrogen may act as an inducer that causes female in high 
risk of thyroid cancer. 
Furthermore, the incidence of thyroid carcinoma in women who take 
oral contraceptives has moderately elevated risk than in those who do 
not (McTieman et al, 1984). An elevated risk was also documented in 
women who used estrogens for gynecological problems, but not for 
low dose estrogen replacement therapy in postmenopausal women 
(Ron et al. 1987 and Persson et al. 1996). These epidemiological 
studies indicate that exogenous estrogen may also promote the 
development of thyroid tumors. 
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1.2 BIOLOGICAL BACKGROUND OF SEX HORMONES 
The process of growth regulation in multicellular organisms is under 
the control of various signals. Among those signals, hormone is one of 
the known factors to regulate cell proliferation. Hormone is a chemical 
substance that is released locally via a paracrine pathway or 
systematically via the circulation system. Hormone is usually produced 
in small amounts but it elicits a typical physiology response in its 
target cells (Figure 3). Hormone usually binds its receptor with 
selectivity to initiate the specific response in the target cell. 
cellular responses 
乂丨 • hormone 
^ - ^ ^ i ^ ^ l n d u c G d proteins 
^mRNA • /y 4 ^^^ hormone^ X^ 
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J transcription ^ ^ \ \ 
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Figure 3. General action of steroid hormone. Steroid hormone passes 
through the plasma membrane and binds to its intracellular receptors. 
Hormone binding activates the receptor, which forms complexes with 
other proteins and binds to specific sites on DNA to initiate 




Estrogen (E2) is a steroid hormone that is traditionally connected with 
female reproduction system. It is mainly synthesized in the ovary, but 
also in peripheral tissues through aromatization of androgen (Cooke et 
al. 1998). It directs the development of the female phenotype in 
embryogenesis and during puberty by regulation of gene transcription 
and, thus, protein synthesis (Beato 1989). It also induces the 
production of gonadotropins, which, in turn, induce ovulation. The 
level of estrogen production is started to decrease in women between 
the ages of 45 and 55 years during menopause. Estrogen deprivation is 
associated with an increase in level of total cholesterol, the risk of 
disabilities related to osteoporosis, genital atrophy and etc. It is an 
extremely important hormone used in the clinic for the prevention and 
treatment of postmenopausal symptoms and as contraceptives. 
However, estrogen is also known as a mitogen that stimulates cell 
proliferation and prevents cell death in many cell types. In patients， 
estrogen is known to stimulate breast and uterus cancer development. 
It is also been shown to prevent apoptosis through an estrogen receptor 
(ER)-mediated mechanism (Thompson 1994). The mitogen-activated 
protein (MAP) kinase (Song et al. 2002), phosphoinositide 3-kinase 
(PI3-kinase) (Sun et al. 2001) and many cell cycle-regulating genes 
8 
(Lodenhofer et al. 2000) are known to be involved in the action of 
estrogen. 
1.2.2. Estrogen antagonist 
Tamoxifen (Tarn) is a non-steroidal selective estrogen receptor 
modulator that inhibits the action of estrogens. It is a mixture of 
estrogen agonist and antagonist, which suppresses tumor growth. It 
has been used in endocrine therapy for many years to treat breast 
cancer patients. The effect of estrogen and tamoxifen on the growth of 
estrogen-dependent breast cancers has been intensively studied. Study 
indicates that the mechanism responsible for the pharmacological 
effect of Tarn is related to its ability to bind to estrogen receptors and 
to form a Tam-estradiol receptor complex, which bind to the nuclear 
binding sites on the genome (Pienta et al. 1995). The binding prevents 
the receptors from recycling thereby reducing the number of receptor 
molecules available for subsequent estradiol activity (Goodman and 
Oilman 1985 and Jordan et al. 1977). Therefore, the mitogenic and 
survival effects of estrogen have been further confirmed by 
observations that the anti-estrogen tamoxifen block breast cell 
proliferation (Budtz et al. 1999 and Spyridopoulos et al 1997). 
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1.2.3. Estrogen receptors 
Estrogen activity is mediated by its cellular receptors (ER). Binding of E2 
to the ER induces a conformational change that enables the ER to recruit 
transcriptional coactivitors and to induce the expression of estrogen-
regulated genes (Beato, 1989). To date, two isoforms of the ER (a and p) 
(Figure 4) have been identified and both subtypes are able to bind to DNA 
as homo- or heterodimers (Pace et al., 1997). ERs are found in reproductive 
tissues and higher centers in the central nervous system that are involved in 
reproduction. However, they are also expressed in non-reproductive tissues, 
like thyroid and endothelium (Kawabata et al. 2003, Macpherson et al. 
1999). Changes in the level of sex steroids are associated with the 
expression of their respective receptors. In endothelial and breast tissues, 
the expression of ER isoforms appears to be up regulated by 17beta-
estradiol during the menstrual cycle. But this effect appears to be tissue- or 
cell- specific (Zou et al 1998，Santagati et al. 1997). 
The expression of ERa is not detected in the normal thyroid gland, but the 
expression of ERp is detected throughout the development of the normal 
thyroid gland in a study by Kawabata et al ERp immunoreactivity was 
detected throughout the development of human thyroid gland from 11 
weeks pregnancy when the large quantity of estrogen was produced in 
placental. The result suggested that estrogen may be involved in the 
10 
development of fetal thyroid gland and these effects may be mediated via 
ERP. 
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Figure 4. The ERa and ERp are activated and dimerized to form a 
transcription unit at an estrogen response element (ERE) in the 
promoter region of an estrogen responsive gene. The expression of 
ERa or ERP target gene is subsequently induced (Handerson 2003). 
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1.2.4. Estrogen receptor and thyroid cancer 
The presence of ERa has previously been examined in human thyroid 
neoplasms by a number of investigators (Dalle et al. 1998; Hiasa et al, 
1993; Bonacci et al. 1996). ERa immunoreactivity was detected in the 
nuclei of thyroid parenchymal cells of various thyroid lesions. 
However, results from these studies were inconsistent, possibly 
because of the different methods employed. Recently, ERa has been 
studied by the immunohistochemical staining in combination with 
labeling index, the most reliable method for detecting ERa in clinical 
specimens (Kawabata et al 2003). It found that ERa labeling index 
was significantly higher in adenomatous goiters, follicular adenomas 
and thyroid carcinomas than in normal thyroid glands. In the papillary 
carcinoma, ERa labeling index was significantly higher in 
premenopausal women than in postmenopausal women and men of 
various ages. In contrast, there was no significant correlation between 
ERP labeling index and patient age, menopausal status, gender, and 
tumors, histological type. The higher level of ERa labeling index may 
be involved in the activation of tumorigenesis of papillary carcinoma 
in premenopausal female. 
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1.3 THE ROLE OF APOPTOSIS 
Apoptosis is a normal physiological process that regulates cell 
populations and maintains tissue homeostasis (Wyllie et al., 1980). It is 
an active process of self destruction that requires the activation of a 
genetic program that may lead to the change in cell morphology, DNA 
fragmentation, and protein cross linking. Apoptosis can be triggered in 
several ways and it involves many cellular functions (Arscott and 
Baker, 1998). The apoptotic mechanism provides protection of cells 
from the possible consequences of uncontrolled cell proliferation. 
1.3.1 Bcl-family protein 
The Bcl-2 family of proteins has been demonstrated to play a key role 
in the mechanism of apoptosis. There are three classes of proteins that 
play crucial roles in this complex process: the BH3 domain-only 
proteins, the pro-apoptotic proteins, and the anti-apoptotic proteins. 
Bid and Bad, the BH3 domain-only proteins, act as triggers to 
stimulate the multidomain pro-apoptotic proteins Bax and Bak (Wei et 
al, 2001). Bcl-2 and Bcl-xL, by sequestering BH3 domain-only 
proteins, prevent apoptosis (Cheng et aL, 2001，Yang et al., 1995). 
The Bcl-family gene is widely accepted as regulators of cell death 
(Minn et al.，1998 and Chao et al., 1998). The anti-apoptotic and pro-
13 
apoptotic genes are considered dominant regulators of apoptosis. Bcl-2 
and Bcl-xL confer a negative control in the pathway of apoptosis. In 
contrast, Bax and Bak promote cell death by competing with Bcl-2 
either down-regulation of pro-apoptotic genes or up-regulation of anti-
apoptotic genes and thus suppress the growth of tumor cells. Thus, 
heterodimerization between members of the Bcl-2 family of proteins is 
a key to the regulation of cell death (Yin et al, 1994). 
1.3.2 Bcl-family protein and cancer 
The Bcl-family proteins have been widely studied in different kinds 
of cancer research. For instance, Bcl-xL overexpression was found 
in hepatocellular carcinoma specimens in 21 of 33 patients (63.6%) 
and the overall survival rates of the group was definitely poor. These 
results showed Bcl-xL in HCC specimens, suggesting that Bcl-xL 
was a significant prognostic factor for disease progression in human 
HCC. (Watanabe et al 2004) In another study, the 
immunohistochemistry of apoptosis-related proteins in the mucosal 
biopsy of bladder cancers were analyzed after treatment of 
chemoradiotherapy (CRT). The Bax/Bd-2 rate showed a significant 
association with the clinical response rate. The result of this study 
suggested that the combined assessment of Bcl-2 and Bax protein 
expression may be used to predict a clinical response to CRT based 
on the Bax/Bcl-2 ratio determined before therapy. (Hiroaki et al 
14 
2004) Therefore, the expression of Bcl-family proteins is critical in 
determining susceptibility to the abnormal cell growth. 
1.3.3 Estrogen and Bcl-family protein 
The protective role and the growth stimulatory effect of estrogen have 
been intensively studied in various ER expressed cells. Estrogen 
protects neuronal cells and cardiac myocytes from apoptosis by 
regulation of Bcl-family protein level (Christoph et aL, 2001 and 
Pelzer et al, 2000). It has been demonstrated that estrogen stimulates 
cell growth in breast and ovary cancer cells by up-regulating Bcl-2 
expression (Wang et al, 1995 and Bu et al” 1997). In the results of 
these studies, the growth stimulatory effect of estrogen in cancer cells 
may be involved with regulation of bcl-2 family proteins expression. 
Recently, a study shows that E2 also has a growth-stimulatory role in 
thyroid cancer cells, similar to the role of E2 in other ER-expressed 
cells (Manole et al, 2000). However, the effect of estrogen on the 
expression of Bcl-family proteins has not been investigated in the 
thyroid cancer cells. 
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1.4 OBJECTIVES 
In this study, we investigated the effect of estrogen (estradiol, E2) on 
the expression of Bcl-2 family at both member messenger ribonucleic 
acid (mRNA) and protein levels in the papillary human thyroid 
carcinoma cell line KAT5, which has a very low Bcl-2 protein 
expression level (Wang et al. 2001). The expression of ER a and (3 
protein levels in E2 treated KAT 5 cell was studied. We also examined 
the stimulatory effect of the E2 and compared it with the effect of 
testosterone, a male hormone, in the KAT5 by MTT assay. In addition, 
the expression of Bcl-2 family member proteins was investigated in the 
KAT5 cells that were treated with the two sexual hormones. Using 
Western blot analysis, we investigated the anti-apoptotic potential 
(Bcl-xL/Bax ratio) that is believed to be crucial for the regulation of 
apoptosis in thyroid cancer. Bcl-xL, like Bcl-2, protects cells from a 
wide variety of apoptotic stimuli. In contrast, Bax, Bcl-2 like protein, 
binds to and antagonizes the protective effect of Bcl-2 and Bcl-xL, and 
renders cells more sensitive to death stimuli. In this sense, the ratio of 
expression of Bcl-xL to Bax appears to determine cell fate in an 
adverse microenvironment. Moreover, the expression of Bcl-xL and 
Bax mRNA was studied to see whether mRNA data consistent with the 
level of protein expression. The results indicate that the action of on 
the growth of KAT5 cells may be associated with up-regulation of Bcl-
xL gene at both mRNA and protein levels. 
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CHAPTER TWO: GENERAL MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Culture Media and treatment Agent 
Material Supplier 
Charcoal treated FBS HyClone (Logan,Utah) 
RPMI 1640 without phenol red GIBCO-BRL (Carlsbad, CA) 
Penicillin/ampicillin/streptomycin GIBCO-BRL (Carlsbad, CA) 
Beta-estradiol Sigma (St. Louis, MO) 
Testosterone Sigma (St. Louis, MO) 
Trypsin-EDTA GIBCO-BRL (Carlsbad, CA) 
Tamoxifen Sigma (St. Louis, MO) 
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2.1.2 Reagents for Western Blot 
Material Supplier 
PMSF Sigma (St. Louis, MO) 
Sodium Orthovanadate Sigma (St. Louis, MO) 
Aprotinine Sigma (St. Louis, MO) 
Acrylamide/Bis-acrylamide Boehringer Mannhein 
(Mannheim, Germany) 
Dithiothreitol (DTT) Sigma (St. Louis, MO) 
Nonidet P-40 Amersham(Buckinghamshire.UK) 
Proteins molecular weight marker Amersham(Buckinghamshire.UK) 
Full range rainbow marker 
ECL membrane Amersham(Buckinghamshire.UK) 





Mouse monoclonal anti-Bcl-xL IgG Santa Cruz (Santa Cruz, CA) 
Mouse monoclonal anti-Bax IgG Santa Cruz (Santa Cruz, CA) 
Rabbit polyclonal anti-ERa IgG Santa Cruz (Santa Cruz, CA) 
Rat monoclonal anti-P tubulin IgG Abeam (Cambridge, UK) 
Goat anti-mouse HRP-IgG Santa Cruz (Santa Cruz, CA) 
Goat anti-rabbit HRP-IgG Santa Cruz (Santa Cruz, CA) 
Rabbit anti-rat HRP-IgG Santa Cruz (Santa Cruz, CA) 
2.1.4 Materials for RT-PCR 
Material Supplier 
Agarose Sigma (St. Louis, MO) 
Blue/orange 6x loading dye Promega (Madison, WI) 
Taq DNA polymerase Promega (Madison, WI) 
DNA ladder Markers (Ikb, 1 OObp) Promega (Madison, WI) 




RNeasy Mini Kit Qiagen (Cologne, Germany) 
Reverse Transcription system Promega (Madison, WI) 
Protein DC Assay Bio-Rad (Hercules, CA) 
ECL Western Blot Detection Kit Amersham(Buckinghamshire,UK) 
2.1.6 Instrumentation 
Instrument Supplier 
Eppendorf centrifuge 5415D Eppendorf (Hamburg, Germany) 
Eppendorf centrifuge 5417R Eppendorf (Hamburg, Germany) 
Mini orbital shaker Bibby (Staffordshire, UK) 
RNA/DNA calculator Amersham(Buckinghamshire,UK) 
UV gel documentation System UVItec limited (Cambridge, UK) 
GeneAmp PGR system 9600 Perkin Elmer (Foster City, CA) 
Mini trans-Blot cell Bio-Rad (Hercules, CA) 
Model GS-700 imaging Bio-Rad (Hercules, CA) 
densitometer 
Molecular Devices microplate reader Tecan Spectra (Princeton, NJ) 
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2.2 Methods 
2.2.1 Cell Culture and Treatment 
The monolayer of the human thyroid papillary carcinoma cells 
KAT5 was grown in RPMI 1640 medium supplemented with 10 % 
FBS, 100 U/mL penicillin and lOOug/mL streptomycin. At 70 %-80 
o/o confluence of KAT5 cells, the cell was trypsinized by 1 % 
EDTA-Trypsin. After centrifugation and aspiration of the 
supernatant, the cells were plated at 2 x 10^  cells/plate in 12 ml 
phenol red free RPMI 1640 supplemented with 0.5-1 % charcoal-
stripped FBS in 100 x 15 mm plates. The cells were then grown at 
37 °C in 5 % CO2 for 48 hours before stimulation with beta estradiol 
or testosterone. After 48-hour incubation, beta estradiol and 
testosterone at various concentrations (both at 10"'', 10"^ , and 10'^  
mol/L), and vehicle (0.02 % EtOH) were added to the KAT5 cells 
in fresh medium, and the cell cultures were incubated at 37 °C in 5 
0/0 CO2 for 1 and 2 days. 
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2.2.2 MTT Assay 
Cell viability was assessed by the mitochondrial dependent 
reduction of 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) to formazan. KAT5 cells were incubated with 10'", 
10-9, and 10"^mol/L of either beta-estradiol or testosterone in 96 
well-plates before the addition of MTT. After the removal of 
conditioned medium, the cells were incubated with MTT in medium 
(0.5mg/ml) for 3 hours. The purple formazan product was 
solubilised in 0.04N HCl-isopropanol. The absorbance of each 
sample at 570nm was measured using a Molecular Devices 
microplate reader. The percentage of living cells was calculated by 
the following formula: absorbance of the treated well/absorbance of 
the control well x 100 %. 
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2.2.3 Western Blot Analysis 
2.2.3.1 Protein Extraction 
Cells were rinsed with PBS and scraped off the cell culture plates 
with lysis buffer containing 1 % Nonidet P-40, 0.5 % sodium 
deoxycholate, 0.1 % SDS, PMSF, aprotinin, and 0.1 mM sodium 
orthovanadate. The cells were further disrupted and homogenized by 
passing through a 21-gauge needle. Having incubated on ice for 1 
hour, the cell lysate was centrifuged at 12000 rpm for 10 minutes at 
4 °C. The concentration of protein was determined using the Bio-
Rad DC Protein assay. The protein samples were kept at -20 °C. 
2.2.3.2 SDS-PAGE electrophoresis and protein transfer 
The protein sample was mixed with 6X sample buffer and denatured 
by boiling at 95 °C for 5 minutes. 30 micrograms of protein per lane 
were loaded and separated on a 10-12 % SDS-polyacrylamide gel. 
Electrophoresis was carried out at room temperature at 100 V for 1.5 
hours. The gel was calibrated with Rainbow markers. After 
electrophoresis, the protein was electrotransferred onto a Hybond 
ECL Nitrocellulose membrane using a Bio-Rad Mini Trans-Blot 
Cell at 4�C，100 V for 1 hour. 
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2.2.3.3 Immunoblotting analysis 
After protein transfer, the membrane was blocked by 5 % nonfat dry 
milk in 1 X TBST buffer (10 mM Tris-HCl, pH 7.5，100 mM NaCl, 
0.1 % Tween-20) for 1 hour. They were then incubated with a 
relevant primary antibody overnight at cold room, washed three 
times with TBST buffer and then incubated with a correspondent 
HRP-conjugated secondary antibody for two hours at room 
temperature. The name and the condition of the antibodies used were 
listed in Table 2. 
Table 2. Antibodies used for immunoblotting analysis 
Primary Antibody Dilution Second Antibody Dilution 
Bcl-xL mouse monoclonal IgG 1:250 Goat anti-mouse HRP-IgG 1:1000 
Bax mouse monoclonal IgG 1:500 Goat anti-mouse HRP-IgG 1:1000 
ERa rabbit polyclonal IgG 1 : 5 0 0 G o a t anti-rabbit HRP-IgG 1:1000 
Tubulin rat monoclonal IgG 1:1000 Rabbit anti-rat HRP-IgG 1:1000 
After the membrane was washed for three times by TBST buffer, an 
enhanced chemiluminescene (ECL) system was applied on the 
membrane. The membrane was exposed to ECL films from 30 seconds 
to 5 minutes, depending on the intensity of the targeted signal. 
Quantitation of the protein was performed with GSP-700 scanner with 
Quantity One image software (Hercules, CA). 
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2.2.4 RNA extraction and RT-PCR 
2.2.4.1 RNA Extraction 
Total RNA was isolated with the RNeasy Kit from QIAGEN and 
performed according to the manufacturer's instruction. Briefly, the 
cell pellet was washed with PBS once, and then was disrupted by 
Buffer RLT with P-ME. After lysate was homogenized to shear 
genomic DNA and reduce viscosity of lysate with QIA shredder 
column, 1 volume of 70 % ethanol was added to adjust the binding 
condition. Subsequently, the mixture was applied to RNeasy mini 
spin column for adsorption of RNA to a membrane. Contaminant 
was removed by simple wash spins (buffers RWl and RPE). The 
total ready-use RNA was eluted with RNase-free water and stored 
at -70 °C. The concentration of the RNA sample was determined 
using a DNA/RNA reader. 
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2.2.4.2 cDNA synthesis 
The 1 |ig of total RNA was used to synthesize cDNA in a reaction 
mixture containing 15U AMV reverse transcriptase. The reaction 
was carried out in a 0.5ml eppendorf tube at 42°C for 45 minutes. 
After reaction, the tube was heated at 99°C for 5 minutes to 
inactivate the enzyme and thus stop the reaction. 
Reverse transcription lOX Buffer 2 jiL 
DNTP mixture (1 OmM) 2 ^L 
MgC12 (25mM) 4 |aL 
RNasin Ribonuclease Inhibitor 0.5 jiL 
AMV reverse Transcriptase (20u/|iL) 0.75 |iL 
Oligo (dT)i5 0.5 |ig 
Total RNA template 1 ^g 
Nuclease-free water to final volume 20 |iL 
2.2.4.3 Polymerase Chain Reaction (PCR) 
The synthesized cDNA was used for PCR to amplify the target gene. 
All of the reactions in this study were carried out under the same 
condition. The reaction was set up as follows: 
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lOx PGR buffer 2 i^L 
dNTP (lOmM) 2 i^L 
MgCl2(25mM) 1 i^L 
Primer (Forward) 0.5 |j,L 
Primer (Reverse) 0.5 \iL 
Nuclease-free H2O 12.5 |j.L 
Taq (5U/|iL) 0.5 \iL 
Template 1 |iL 
Total Volume 20 ^L 
PGR amplification was performed using a programmable thermal 
cycler. Reactions were carried out at 94 °C for 2 min; 30 cycles of 
94 °C for 35 sec, 58.6 °C for Bcl-xL or 49 °C for Bax or 62 °C for P 
actin for 35 sec, 72 °C for 35sec; and then 72 °C for 10 minutes and 
4 °C to terminate the reaction. Electrophoresis of 5|il of each PGR 
reaction was performed in a 1 % agarose gel. The primers used were 
detailed in Table 3. 
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Table 3. Sequences and positions of synthetic oligomers used in this study: 
Primer Sequence Orientation 
B a x a F 5，-T T T TCT GAC GGC A AC TTC -3 , Sense 
B a x a R 5，-G C G AGG CGG TGA GCA CTC C-3, Antisense 
Bcl-xL F 5'-CAT CAC CCC AGG GAC AGC ATA TC-3' Sense 
Bcl-xL R 5,-TGG TCA TTT CCG ACT GAA GAG T G - 3 ' ~ Antisense 
P actin F 5'-GCA TTT GCG GTG GAC GAT GGA GG-3’ Sense 
P actin R 5'-GGT CAC CCA CAC TGT GCC CAT CTA-3' Antisense 
2.2.5 Statistical Analysis 
The statistical analysis was performed using a SPSS 8.0 for 
Windows (SPSS, Inc.，Chicago, IL). ANOVA for repeated 
measurements was applied to compare cell viability MTT assay and 
the level of target proteins in the cell treated with different 
concentrations of E2 and testosterone. 
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CHAPTER THREE: RESULTS 
3.1 Effect of E2 and tamoxifen on proliferation 
The viability percentage of KAT5 cells treated with E2 was 
determined by the MTT assay. The viability percentage was 
calculated as dividing the absorbance 570nm of wells with E2 
treatment by the absorbance 570nm of the untreated cell and 
multiplied by 100. The data was presented as the mean of living cell 
percentage in four individual experiments on y-axis versus the 
different E2 treatments on x-axis. As shown in Figure 5A, E2 at 
concentrations of 10"^  and 10"^  M caused a significant increase in 
cell proliferation at 24-hour incubation compared with untreated 
cells and 10"" M E2 (*P<0.05, n=4), and the increase reached a 
plateau after the concentration of E2 reached 10"^  M. In 48-hour 
culture (Figure 5B), the increase was reduced after the concentration 
of E2 reached 10'^  M. The highest proliferative effect of E2 was 
observed at 10"^  M in 24 and 48 hour incubations. The growth of 
cells was statistically decreased in the cells treated with tamoxifen 
plus E2 compared with the cells received no tamoxifen treatment 
(AP<0.05，n=4). The cotreatment with E2 plus tamoxifen (10'^ M) 
could attenuate the effect of E2 in KAT5 cells to the level of 
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Figure 5A andB. The proliferation of KAT5 cells determined by 
MTT assay. A significant increase was observed {versus untreated 
cells, *P<0.01, n=4) in response to E2 in both 24- and 48-hour 
incubations. Such an increase was markedly reduced after the 
addition of tamoxifen (versus each treated cells, ^P<0.05, n=4). 
Data are the mean 士 S.D. of 4 separate experiments. 
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3.2 Comparison of effects of E2 and Testosterone on proliferation 
To compare the effects of E2 and Testosterone on cell proliferation in 
KAT5 cells, the cells were treated with InM of E2 or Testosterone for 12， 
24，36 and 48 hours. The absorbance of 570nm for formazan product in 
MTT assay was measured as previously described. Treatment with E2 
affected the growth of KAT5 and reached the maximum growth in 24 
hours, whereas Testosterone treatment for 24 hours resulted in a decrease 
of the growth in KAT5 (Figure 6). The growth of KAT5 was plateau after 
36 hours treatment with E2. In contrast, treatment with testosterone 
slightly increased the growth of KAT5 in 36 hours, but it was also 
observed in the control group. Therefore, stimulatory growth effect 
appeared to be specific to E2 and the effect was dose dependent. 
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Figure 6. Effect of E2 and testosterone on cell proliferation. To 
compare the effect of E2 and testosterone on the growth of KAT5 
cells, the cells were treated with 1 nM of E2 and testosterone for 12, 
24，36 and 48 hours. The absorbance of 570 run was analyzed 
following the addition of MTT substrate after different incubation 
periods indicated. Data are shown as the mean of four individual 
experiments and presented as the mean 士 S.D. (*P<0.05 versus 
untreated group at specific time point, n=4). 
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3.3 Differential Bcl-xL expression in response to E2 and testosterone 
stimulation. 
To compare the effects of E2 and testosterone on the expression of 
Bcl-xL (31 kDa) in KAT5, different concentrations of E2 or 
testosterone (10'' ' M, 10"^  M，and 10'^  M) were added to the KAT5 
cells and incubated for 24 hours. Mouse monoclonal antibody for Bcl-
xL and rat monoclonal antibody for tubulin were used in the Western 
blot analysis. The Western blot analysis showed that E2 clearly 
increased in the level of Bcl-xL in a dose-dependent manner. The 
maximal effect was found at the concentration of 10"^  M (Figure 7). 
Unlike E2, in KAT5 cells stimulated with testosterone, the level of 
Bcl-xL remained constant for three concentrations of testosterone 
tested, which were not different from untreated cells. Tubulin (52 kDa) 
expression was used to check the loading size into each lane. 
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Figure 7. Expression of Bcl-xL protein. The level of Bcl-xL (31 kDa) 
protein in KAT5 treated with E2 and testosterone was investigated by 
Western blot analysis. The protein amount was normalized by tubulin 
protein (52 kDa). At least three individual experiments were performed. 
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3.5 Bcl-xL and Bax protein expression in response to E2 stimulation 
To investigate the expression of ERa and ERp in E2-stimulated KAT5 
cells, Western analysis was performed using the mouse monoclonal 
antibody for ERa and the goat polyclonal antibody for ERp. As shown 
in Figure 8, ERa protein (68 kDa) was observed in untreated and 
treated cells. The result indicated that the expression of ERa remains 
constant in the increasing E2 treatment concentration in 24 hours, and 
the expression of ERa was increased in dose dependent manner in 48 
hours. In contrast, the expression of ERp was much lower than the 
expression of ERa. The expression of ERP was hardly detected in all 
samples (Figure 8). 
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Figure 8. Effect of E2 treatment on the expression of ERa and ERp 
proteins in KAT5 cells. The protein level was investigated by Western blot 
analysis. The ERa and ERP were expressed at the size of 68 kDa and 55 kDa. 
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3.5 Bcl-xL and Bax protein expression in response to E2 stimulation 
Western blot analysis was used to determine relative levels of Bcl-xL and 
Bax protein in each of the three E2 treatment groups, and tubulin was 
used to monitor sample loading (Figure 9A). Cells treated with E2 for 24 
hours showed a clear increasing Bcl-xL protein level, compared with that 
in the control group. No difference was observed in the expression of 
Bcl-xL protein in 48-hour incubation. The expression of Bax protein 
appeared unchanged in all samples treated with E2 at both time points. 
The ratio of anti-apoptotic Bcl-xL to pro-apoptotic Bax was used as a 
relative indicator of anti-apoptotic potential (Adams and Cory 2001). 
This study determined this ratio by measuring the density of the target 
protein bands. Cells treated with E2 showed (Figure 9B) a significant 
increase in the ratio of Bcl-xL to Bax compared with that in control group 
in 24-hour incubation. There was no significant difference in ratio of Bcl-
xL to Bax between untreated cells and cells treated with E2 in 48-hour 
incubation. The increased anti-apoptotic potential in the cells treated with 
E2 for 24 hours was consistent with the result of the E2 growth-
stimulated effect obtained by MTT analysis. 
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Figure. 9A Effect of E2 on the expression of Bcl-xL (31 kDa)，Bax 
(24 kDa) and tubulin (52 kDa) proteins in KAT5. Lanes 1-4: 24-hour 
treatment. Lane 1: control; Lane 2: Lane 3 : lO'^M; Lane 4 : 10" 
^M. Lanes 5-8: 48-hour treatment. Lane 5: control; Lane 6: 10'' 
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Figure 9B. The semi-quantitative analysis of the Western blots of 
anti-apoptotic potential (Bcl-xL/Bax ratio). The Bcl-xL and Bax protein 
bands were scanned. Their densities were determined by and the ratio of 
Bcl-xL and Bax was calculated. Significant difference was determined 
using one-way ANOVA(* P<0.05 versus untreated for 24-hour group). 
At least three separated experiments were performed. 
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3.5 Bcl-xL and Bax protein expression in response to E2 stimulation 
The mRNA levels of pro-apoptotic Bax and anti-apoptotic Bcl-xL in 
KAT5 cells were investigated by RT-PCR. PCR products of actin, Bax 
and Bcl-xL were obtained as 649 bp, 256 bp, and 367 bp respectively 
(Figure 10). No difference was observed in expression level of Bax 
mRNA in three concentrations of E2 -treated KAT5 cells. In contrast, 
the expression of Bcl-xL mRNA was increased in a dose-dependent 
manner, which was similar to the expression of Bcl-xL protein result in 
the previous Western blot analysis results. 
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Figure 10. Effects of E2 on the levels of Bax and Bcl-xL mRNA. To 
investigate the mechanism of E2 in the stimulation of growth, the regulation of 
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Bax and Bcl-xL was examined using RT-PCR in KAT5 cells. The cells were 
treated with E2 for 24 hours. As expected the sizes of PGR products for Bcl-
xL and Bax were 367 bp and 256 bp respectively. At least three individual 
experiments were performed. 
40 
CHAPTER FOUR: DISCUSSION 
Tissue homeostasis is regulated in part by factors that control the appropriate 
balance between cell proliferation and cell death. If tumors are to arise they 
must successfully bypass the cell-killing program that is activated in response 
to genetic and environmental factors (Fagin 1998). E2 has been studied as one 
of the factors that influence tumorigenesis in various ER expressed cells (Gao 
et al. 2002, Franke et al. 2002, and Choi et al. 2000). In breast cancer cells, 
the E2 in a concentration of 10"^  M induced proliferation in ER+ breast 
o ^ 
carcinoma cells. In addition, treatment with exogenous E2 (10" -10" M) 
resulted in a growth stimulation of tumorigenic ovarian cell line by up-
regulating the anti-apoptotic Bcl2 mRNA and protein. In uterine leiomyoma 
cells, E2 (10 ng/ml) treatment significantly decreased the tumor suppressor 
p53 protein level to regulate the growth of the cancer cells. Thyroid tumors 
highly express ER (Inoue et a/. 1993, Yane et a/. 1994，and Clark et a/. 1985) in 
the same way as estrogen-dependent carcinomas such as those of ER 
expressed breast, ovarian and uterine tissues. Recently, the growth-promoting 
effect of E2 in benign and malignant thyroid cells has been confirmed and 
extended to its influence in the regulation of cell cycle by inducing cyclin D1 
protein levels (Manole et a/.2001). However, the mechanism how E2 affects 
the programmed cell death has not yet been investigated in thyroid cancer cells. 
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The present study first tested whether sex hormones had any effect on the 
proliferation and growth of human thyroid cancer cell, KAT5 papillary thyroid 
carcinoma cell. The result demonstrated the specificity of E2 on growth 
promotion in KAT5 that tamoxifen reversed the effect of E2 on the cell, 
suggesting that the proliferation of KAT5 cells by E2 was mediated through its 
specific receptors. Treatments of E2 (10'^' M to 10'^  M) increased the growth 
of KAT5 cells in both 24- and 48-hour incubation. But the stimulatory growth 
effect of E2 was not significant at lO'^ ^M E2 treatment at 24-hour incubation 
and it reached a plateau at the concentration of 10"^  M in 24-hour incubation. 
In addition, the growth effect of E2 was decreased at the concentration of 10"^  
M when the incubation time was 48-hour. The similar result was also 
demonstrated by Yu et al. 1996. Yu et al reported that E2 at low concentrations 
has no stimulatory effect on the growth of human thyroid carcinoma cell lines 
in 24-hour incubation. However, these authors reported a marked reduction in 
the proliferation of the thyroid cancer cell lines exposed to the E2 
concentration at 10'^  M. Taking together the data from the present study and 
that of Yu et al., it implied that the growth effect of E2 was in a dose 
dependent manner. 
The effects of E2 and testosterone on cell proliferation in KAT5 cells were 
compared by treating the cells with InM of E2 and testosterone for 12, 24, 36 
and 48 hours. The result showed that E2 increased the cell proliferation and 
that its effect reached the maximal effect at the 24-hour point of treatment. In 
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contrast, testosterone markedly decreased the cell proliferation in 24-hour 
incubation, though the reduction of the cell proliferation was also found in the 
control group. Thus, the result suggested that E2 and testosterone differentially 
affected the proliferation of the KAT5 cells. Also, the Bcl-xL expression in 
KAT5 cells was determined by Western blot after treatments of E2 and 
testosterone for 24 hours. E2 clearly increased the level of Bcl-xL in a dose-
dependent manner. Unlike E2, testosterone did not cause any difference 
between treated and untreated KAT5 cells in the level of Bcl-xL expression. 
The differential effects of E2 and testosterone on the proliferation of KAT5 
cells and the expression of Bcl-xL level in KAT5 cells provided a good 
laboratory evidence, that sex steroids may be one of the factors underlying the 
gender bias in thyroid cancer incidence. Thus it may explain the 
epidemiological observation that thyroid cancer occurs predominantly in 
females, especially those in their reproductive age. 
The effect of E2 is believed to be closely associated with its receptors. Two 
estrogen receptor isoforms have been identified. It has subsequently shown 
that ERa and ERp proteins can create three possible transactivating factor 
combinations- ERa homodimers, ER(3 homodimers and ERa-ERp 
heterodimers in several experimental systems (Pace et al. 1997, Petterson et al. 
1997). These dimers bind to their specific estrogen response elements (EREs) 
that initiate transcription of specific genes. Therefore, differential gene 
expression in a cell will be determined by the ER expression and its promoters. 
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In present study, the results showed that ERa expression was higher than ERp 
expression in KAT5 cells treated with the three different E2 concentrations at 
both 24- and 48-hour points of time. The ERa expression was slightly 
increased in the cell treated with E2 for 48 hours however it remained 
unchanged in the cell treated for 24 hours. In contrast, the ERp expression 
remained unchanged in all conditions at all points of time. A similar result was 
also found by Manole et al 2001. They found that the level of ERa had a 
maximal expression at 48-hour in different E2 concentrations, and the ERp 
expression remained constant in the human thyroid carcinoma cell line. In 
another study by Choi et al. 2000，the expression levels of ERa were enhanced 
in ovary carcinoma cells when compared with those in normal ovaries, 
whereas ERp levels were significantly decreased in ovarian tumors. The result 
suggested that differential expression of ERa and ER|3 in the tumors may be 
altered in response to estrogen treatment and the expression of ERa may be 
specific in response to E2 in the KAT5 tumor cells. 
Among pro-apoptotic and anti-apoptotic genes in Bcl-2 family, the expression 
of Bax and Bcl-2 genes has been studied as the dominant regulators for 
apoptosis. The ratio of Bcl-2 to Bax was important in determining 
susceptibility to apoptosis (Chao et a J 1998). The present study has 
demonstrated that Bax and Bcl-xL, a homolog of Bcl-2, were expressed at 
both mRNA and protein levels in KAT5 cells. No difference was observed in 
the expression level of Bax mRNA among the different E2 treated-KAT5 cells. 
In contrast, treatment with E2 resulted in an obvious increase of Bcl-xL 
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mRNA level. These findings were in agreement with a previous report where 
estrogen up-regulated anti-apoptotic Bcl-2 gene, whereas Bax level was not 
affected by E2 in breast cancer cells (Perillo et al 2000). The up-regulation of 
Bcl-xL by E2 suggested that E2 affected the survival of KAT5 cells through a 
pathway involved with Bcl-xL, which was known to be a regulator of 
apoptosis (Pike 1999, Leung et al 1999). In the study by Leung et al. (1999), 
it showed that estrogen down-regulated anti-apoptotic Bcl-xL mRNA and up-
regulated anti-apoptotic Bcl-2 mRNA and protein in a dose-dependent manner 
in breast cancer cells, suggesting that members of bcl-2 family may be 
differently regulated in different types of cancer cells. In parallel with mRNA 
level, E2 caused a significant up-regulation of Bcl-xL protein level, whereas 
no difference was observed in Bax protein level. KAT5 cells treated with E2 
for 24 hours showed a significant up-regulation of the ratio of Bcl-xL to Bax 
compared with that in control cells. 
However, the increased ratio of Bcl-xL to Bax by E2 treatment was reduced as 
there was no significant difference in this ratio between untreated cell and 
cells treated with E2 while the growth of KAT5 cell still increased in dose-
dependent manner in range of lO'^ ^M to lO'^M of E2 treatment at 48-hour 
incubation. E2 can trigger multiple signaling pathways, such as MAP kinases, 
PI3-kinases, Protein Kinase A (PKA) and cyclin D1 (Kelly et al. 1999, Manole 
et al 2001，Sun et al 2001). In addition, the ligand-bound estrogen receptor 
can bind to estrogen responsive element (ERE) in the promoter region of 
estrogen-responsive genes and activate these genes, such as c-myc, c-fos, Ap-1， 
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FasL (Mor et al 2000，Kelly et al. 1999，Santen et al 2001) and Bcl-2. For 
example, changes in protein profile during the adaptation of breast cancer cells 
to long-term estrogen deprivation have been demonstrated previously, 
involving up-regulation and activation of several critical regulatory proteins, 
such as c-Myc, c-Myb, MAP kinase, E2F1, and Ras (Chen et al 2000, Cobb et 
al. 1999，Prendergast et al 1999). These proteins can mediate the action of 
hormones and growth factors by exerting stimulating proliferation on the one 
hand or inducing apoptosis on the other, depending on the conditions (Bacus et 
al. 2001，Evan et al. 1998). In this study, estrogen did affect cell proliferation 
in papillary human thyroid carcinoma cells, KAT5 cells, and the mechanism of 
estrogen in regulation of anti-apoptotic pathway may be associated with up-
regulation of Bcl-xL gene. 
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CHAPTER FIVE: CONCLUSION 
Taken together the data from the present study and that of other previous 
studies, it becomes clear that the effect of E2 on growth of thyroid carcinoma 
cells may involve more than one pathway. The present study demonstrates that 
E2 promote papillary thyroid cell growth in part through the apoptotic pathway 
by up-regulating Bcl-xL. It may provide the insights into the molecular 
mechanism underlying the epidemiological data that show a prevalence of 
thyroid carcinomas 2- 3 folds more in females than in males. From the 
therapeutic point of view, the finding that the enhancement of anti-apoptotic 
signaling by E2 may be significant in the prevention or treatment of thyroid 
tumors, because anti-estrogen or anti-ER medication can inhibit the growth of 
thyroid cancer cells via a pathway pf promoting apoptosis. 
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